Business Wire

TX-MAVENIR

Share
Mavenir’s Cloud-Native Open vRAN and Packet Core Achieves GSMA NESAS Security Certification

Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced that it achieved GSMA’s Network Equipment Security Assurance Scheme (NESAS) security certification in November 2021. Mavenir is the 6th global mobile network provider to receive accreditation , joining vendors including Nokia, Ericsson, and Samsung to have undergone an assessment and independent audit of their development and product lifecycle processes to evidence how security is integrated into their design, development, implementation, and maintenance processes.

The GSMA NESAS, jointly defined by 3GPP and GSMA, provides an industry-wide security assurance framework to facilitate improvements in security levels across the mobile industry.

Mavenir completed the certification across Mavenir’s portfolio including:

  • Open Virtualized 5G & 4G Radio Access Network (Open vRAN): fully containerized Open vRAN solution including Centralized Unit (CU) and Distributed Unit (DU).
  • 5G & 4G Packet Core: cloud-native and fully containerized mobile core.
  • Mavenir Webscale Platform (MWP): cloud-native solutions that include Kubernetes based CaaS (Containers as a Service), PaaS (Platform as a Service) and MTCIL (Telecom PaaS layer) along with a management layer with full FCAPS, analytics, slice management and service orchestration.

“As the industry’s only, end-to-end cloud-native network software provider, providing secure products and solutions is of paramount importance to Mavenir. We are pleased to achieve this important GSMA NESAS milestone for our cloud-native products including vRAN, Packet Core and Containerized Platform. It is vital that open and cloud-native solutions implement a secure product life cycle and methodology for all design, implementation and operational processes,” says Mike Barnes, Head of Product Security and Quality at Mavenir and Co-chair of the FCC’s Communications Security, Reliability and Interoperability Council (CSRIC) VIII WG2 on Open RAN security.

Mavenir’s GSMA NESAS certification is a significant milestone which demonstrates resilience in mitigating potential security vulnerabilities and the capability to provide robust, secure traditional and open solutions. NESAS compliance establishes that appropriate security principles are integrated into Mavenir’s design, development, implementation and operational processes.

GSMA’s NESAS provides a security assurance framework to enable continued improvements in security levels across the mobile industry for secure product development and product lifecycle processes, used by traditional network equipment providers as well as network software vendors. NESAS helps avoid fragmentation of security requirements by providing a common set of security assurance and baseline against which network equipment has been developed in accordance with vendor’s development and product lifecycle processes.

About Mavenir:

Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

Illumynt Reports Q3 2025 Business Update17.10.2025 14:39:00 CEST | Press release

Q3 2025 was a busy quarter once again for us here at illumynt. In addition to naming a new CEO, we executed on a number of initiatives that are propelling our organization forward. Revenue for the quarter exceeded $30 million- keeping us on track for our 2025 plan. More importantly we executed three different large-scale data center decommission projects with almost no material ending up as scrap. All of the AI-focused enterprise equipment and components recovered from the decommissions were resold at top market value. We head into Q4 with high expectations and our eyes wide open. We’re celebrating the 20-year anniversary of our facility in Hong Kong and looking to add another location in the region to help us process inbound AI data center equipment. Stay tuned for updates. There will be more on the way. View source version on businesswire.com: https://www.businesswire.com/news/home/20251017446548/en/

Avanzanite Bioscience’s Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia17.10.2025 14:15:00 CEST | Press release

Avanzanite entered an exclusive partnership with Agios in June 2025 to manage PYRUKYND commercialization across Europe European Commission will now review the CHMP’s opinion, with the final decision expected by early 2026 PYRUKYND is currently approved in Europe for adults with PK deficiency; thalassemia would represent its second indication, pending European Commission approval Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the new indication for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for t

Kinaxis Accelerates Agentic Era for Supply Chain Orchestration with the Launch of Maestro Agents17.10.2025 13:00:00 CEST | Press release

AI agents that plan with you, not just for you, empower the customer journey to a next generation of the adaptive supply chain Kinaxis® Inc. (TSX: KXS), a global leader in supply chain orchestration, today announced Maestro Agents, marking the next milestone in AI-enabled decision intelligence for supply chains. Now available to Kinaxis customers and embedded natively in Kinaxis Maestro®, these AI-powered context aware digital co-workers help planners move faster from issue to action, turning disruption into opportunity, and strengthening the resilience of the supply chains that power the global economy. “Kinaxis agents are already helping our planning team collaborate more effectively with customers and contract manufacturers,” said John Finnigan, Senior Director, Advanced Planning at Jabil. “With human-in-the-loop safeguards, we’re reaching decisions faster today and see strong potential to build a more resilient and networked supply chain.” Maestro Agents advance the customer journe

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye